|
1
|
Amodeo C, Caglià P, Gandolfo L, Veroux M,
Donati M and Immè A: Undifferentiated carcinoma of the thyroid.
Tumori. 89:(Suppl 4). S205–S206. 2003.(In Italian).
|
|
2
|
Denaro N, Nigro CL, Russi EG and Merlano
MC: The role of chemotherapy and latest emerging target therapies
in anaplastic thyroid cancer. Onco Targets Ther. 9:1231–1241. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kihara M, Miyauchi A, Yamauchi A and
Yokomise H: Prognostic factors of anaplastic thyroid carcinoma.
Surg Today. 34:394–398. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xia J, Bi H, Yao Q, Qu S and Zong Y:
Construction of human ScF phage display library against ovarian
tumor. JJ Huazhong Univ Sci Technolog Med Sci. 26:497–499. 2006.
View Article : Google Scholar
|
|
5
|
McFadden DG, Vernon A, Santiago PM,
Martinez-McFaline R, Bhutkar A, Crowley DM, McMahon M, Sadow PM and
Jacks T: p53 constrains progression to anaplastic thyroid carcinoma
in a Braf-mutant mouse model of papillary thyroid cancer.
Proc Natl Acad Sci USA. 111:E1600–E1609. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Luo Y, Pang H and Li S, Cao H, Peng Z, Fan
C and Li S: Production and radioimmunoimaging of novel fully human
phage display recombinant antibodies and growth inhibition of lung
adenocarcinoma cell line overexpressing Prx I. Cancer Biol Ther.
8:1369–1377. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Qiong L, Hua P, Xi J, Li W and Lu X:
Medullary thyroid carcinoma like humanized phage single chain
antibody screening and identification. Chongqing Yike Daxue Xuebao.
9:12–16. 2015.
|
|
8
|
Duan D, Li SL, Zhu YQ and Wang SB: Effects
of radioimmunoimaging with 99Tcm-EGFR-McAb or
99Tcm-CD44-McAb or combined application of
both on nude mice bearing human lung adenocarcinoma. J Third Mil
Med Univ. 31:1287–1280. 2009.
|
|
9
|
Zhao WS, Luo Y, Li BY, Zhou HJ and Zhang
T: Anti-ABCG2 scFv antibody of lung adenocarcinoma increases
chemosensitivity and induces apoptosis through the activation of
mitochondrial pathway. Am J Cancer Res. 6:1026–1039.
2016.PubMed/NCBI
|
|
10
|
Xi J, Hua P, Sen Z, Qiong L and Li W:
Thyroid without differentiation carcinoma of human scFv antibody
library construction and screening. J Immunol. 31:692–696.
2015.
|
|
11
|
Smallridge RC, Marlow LA and Copland JA:
Anaplastic thyroid cancer: Molecular pathogenesis and emerging
therapies. Endocr Relat Cancer. 16:17–44. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fagin JA, Matsuo K, Karmakar A, Chen DL,
Tang SH and Koeffler HP: High prevalence of mutations of the p53
gene in poorly differentiated human thyroid carcinomas. J Clin
Invest. 91:179–184. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Garcia-Rostan G, Camp RL, Herrero A,
Carcangiu ML, Rimm DL and Tallini G: β-catenin dysregulation in
thyroid neoplasms: Down-regulation, aberrant nuclear expression,
and CTNNB1 exon 3 mutations are markers for aggressive tumor
phenotypes and poor prognosis. Am J Pathol. 158:987–996. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nikiforova MN, Kimura ET, Gandhi M,
Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G,
Fusco A, et al: BRAF mutations in thyroid tumors are restricted to
papillary carcinomas and anaplastic or poorly differentiated
carcinomas arising from papillary carcinomas. J Clin Endocrinol
Metab. 88:5399–5404. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Quiros RM, Ding HG, Gattuso P, Prinz RA
and Xu X: Evidence that one subset of anaplastic thyroid carcinomas
are derived from papillary carcinomas due to BRAF and
p53 mutations. Cancer. 103:2261–2268. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gui PL and Cheng MZ: Tumor
radioimmunoimaging and treatment of a predetermined bit technology.
Foreign Medical Oncology. 25:26–29. 1998.
|
|
17
|
Vezzosi D, Bennet A and Caron P: Recent
advance in treatment of medullary thyroid carcinoma. Ann
Endrocrinol. 68:147–153. 2007. View Article : Google Scholar
|
|
18
|
Rubello D, Rampin L, Nanni C, Banti E,
Ferdeghini M, Fanti S, Al-Nahhas A and Gross MD: The role of
18F-FDG PET/CT in detecting metastatic deposits of
recurrent medullary thyroid carcinoma: A prospective study. Eur J
Surg Oncol. 34:581–586. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Subedi GP, Satoh T, Hanashima S, Ikeda A,
Nakada H, Sato R, Mizuno M, Yuasa N, Fujita-Yamaguchi Y and
Yamaguchi Y: Overproduction of anti-Tn antibody MLS128 single-chain
Fv fragment in Escherichia coli cytoplasm using a novel
pCold-PDI vector. Protein Expr Purif. 82:197–204. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Staelens S, Desmet J, Ngo TH, Vauterin S,
Pareyn I, Barbeaux P, Van Rompaey I, Stassen JM, Deckmyn H and
Vanhoorelbeke K: Humanization by variable domain resurfacing and
grafting on a human IgG4, using a new approach for
determination of non-human like surface accessible framework
residues based on homology modelling of variable domains. Mol
Immunol. 43:1243–1257. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vanden Borre P, McFadden DG, Gunda V,
Sadow PM, Varmeh S, Bernasconi M, Jacks T and Parangi S: The next
generation of orthotopic thyroid cancer models: Immunocompetent
orthotopic mouse models of BRAFV600E-positive papillary
and anaplastic thyroid carcinoma. Thyroid. 24:705–714. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang J, Yu C, Liao L and Liao H:
Expression of human insulin like growth factor-1 in Escherichia
coli induced by lactose. Strait Med. 22:248–252. 2010.
|
